Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP5K1C | O60331 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | CLK3 | P49761 | 1/20 | 0.37 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490691 | 0.90 | PIP5K1C (0.40) | PIP5K1CPIK3CAPI4KAPI4KBSCD | |
| SCHEMBL2492711 | 0.84 | HRH4 (0.55) | PIP5K1CPIK3CAPI4KAPI4KBSCD | |
| SCHEMBL2493489 | 0.83 | HRH4 (0.42) | HDAC3HDAC2CYP1A2CYP2C18CYP2C19 | |
| SCHEMBL2995883 | 0.82 | AXL (0.41) | HDAC3HDAC2CYP1A2CYP2C18CYP2C19 | |
| SCHEMBL2512301 | 0.80 | HRH4 (0.41) | HDAC3HDAC2HRH4 | |
| SCHEMBL2490652 | 0.79 | HRH4 (0.40) | PIK3CAHRH4 | |
| SCHEMBL2990072 | 0.78 | PIK3CD (0.40) | PIK3CAPI4KAPI4KBHRH4 | |
| SCHEMBL2548435 | 0.77 | HRH4 (0.42) | PIK3CAHRH4 | |
| SCHEMBL2508952 | 0.77 | HRH4 (0.40) | PIK3CAHRH4 | |
| SCHEMBL2987808 | 0.77 | HRH4 (0.47) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | claimed |
| US-8436008-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-05-07 | — | — | US | claimed |
| EP-2379523-A1 | 4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS | Incyte Corporation (US) | 2011-10-26 | — | — | EP | claimed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | claimed |
| WO-2010075270-A1 | 4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS | INCYTE CORPORATION (US) | 2010-07-01 | — | — | WO | claimed |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-8436008-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436008-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436008-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2010075270-A1 | 4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS | INCYTE CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173901-A1 | Substituted Heterocyclic Compounds | HRH4, HRH2, HRH1 | PIP5K1C 1520/4885PIK3CA 1098/4885PI4KA 2165/4885 |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | HRH4, HRH2, HRH1 | PIP5K1C 1520/4885PIK3CA 1098/4885PI4KA 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.